Compare Stocks: GRI, FNCH, ELOX, and INTS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ELOX Eloxx Pharmaceuticals	$18.76 -1.6%	$14.30	$8.20 ▼ $19.96	$13.13M	-1864.08	67,098 shs	29,638 shs
FNCH Finch Therapeutics Group	$7.30	$7.30	$2.00 ▼ $16.10	$11.72M	1.18	5,025 shs	N/A
GRI GRI Bio	$1.67 -5.6%	$1.77	$1.36 ▼ $80.36	$2.96M	-1.21	392,580 shs	105,236 shs
INTS Intensity Therapeutics	$3.96 -1.0%	$4.25	$3.51 ▼ $43.50	$12.93M	2.76	26,156 shs	38,949 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ELOX Eloxx Pharmaceuticals	-1.63%	+6.77%	+49.01%	-11.40%	+∞
FNCH Finch Therapeutics Group	0.00%	0.00%	0.00%	-7.80%	-39.92%
GRI GRI Bio	-5.65%	+13.61%	+3.09%	-17.73%	-95.41%
INTS Intensity Therapeutics	-1.00%	-4.81%	-18.18%	-14.47%	-45.38%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ELOX Eloxx Pharmaceuticals	$18.76 -1.6%	$14.30	$8.20 ▼ $19.96	$13.13M	-1864.08	67,098 shs	29,638 shs
FNCH Finch Therapeutics Group	$7.30	$7.30	$2.00 ▼ $16.10	$11.72M	1.18	5,025 shs	N/A
GRI GRI Bio	$1.67 -5.6%	$1.77	$1.36 ▼ $80.36	$2.96M	-1.21	392,580 shs	105,236 shs
INTS Intensity Therapeutics	$3.96 -1.0%	$4.25	$3.51 ▼ $43.50	$12.93M	2.76	26,156 shs	38,949 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ELOX Eloxx Pharmaceuticals	-1.63%	+6.77%	+49.01%	-11.40%	+∞
FNCH Finch Therapeutics Group	0.00%	0.00%	0.00%	-7.80%	-39.92%
GRI GRI Bio	-5.65%	+13.61%	+3.09%	-17.73%	-95.41%
INTS Intensity Therapeutics	-1.00%	-4.81%	-18.18%	-14.47%	-45.38%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ELOX Eloxx Pharmaceuticals	3.00	Buy	$41.50	121.22% Upside
FNCH Finch Therapeutics Group	0.00	N/A	N/A	N/A
GRI GRI Bio	2.00	Hold	$32.00	1,816.17% Upside
INTS Intensity Therapeutics	2.75	Moderate Buy	$37.50	846.97% Upside

Current Analyst Ratings Breakdown

Latest GRI, FNCH, ELOX, and INTS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2026	INTS Intensity Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/22/2026	ELOX Eloxx Pharmaceuticals	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$40.00
7/21/2026	INTS Intensity Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/20/2026	ELOX Eloxx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$43.00
7/20/2026	ELOX Eloxx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$43.00
7/17/2026	GRI GRI Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/1/2026	GRI GRI Bio	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$40.00 ➝ $32.00
5/20/2026	INTS Intensity Therapeutics	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Speculative Buy

(Data available from 8/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ELOX Eloxx Pharmaceuticals	$6.36M	2.04	N/A	N/A	$67.43 per share	0.28
FNCH Finch Therapeutics Group	N/A	N/A	N/A	N/A	$14.25 per share	N/A
GRI GRI Bio	N/A	N/A	N/A	N/A	$4.16 per share	N/A
INTS Intensity Therapeutics	N/A	N/A	N/A	N/A	$2.82 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ELOX Eloxx Pharmaceuticals	-$5.99M	-$15.29	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FNCH Finch Therapeutics Group	-$74.75M	-$8.82	N/A	N/A	N/A	N/A	-69.14%	-26.92%	N/A
GRI GRI Bio	-$11.96M	-$74.16	N/A	N/A	N/A	N/A	-199.52%	-143.23%	N/A
INTS Intensity Therapeutics	-$11.61M	-$5.71	N/A	N/A	N/A	N/A	-116.61%	-94.01%	N/A

Latest GRI, FNCH, ELOX, and INTS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	GRI GRI Bio	-$1.19	-$0.91	+$0.28	-$0.91	N/A	N/A
8/11/2026	Q2 2026	ELOX Eloxx Pharmaceuticals	N/A	-$0.66	N/A	-$0.66	N/A	N/A
8/11/2026	Q2 2026	INTS Intensity Therapeutics	-$0.8725	-$1.11	-$0.2375	-$1.11	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ELOX Eloxx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
FNCH Finch Therapeutics Group	N/A	N/A	N/A	N/A	N/A
GRI GRI Bio	N/A	N/A	N/A	N/A	N/A
INTS Intensity Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ELOX Eloxx Pharmaceuticals	N/A	3.74	0.53
FNCH Finch Therapeutics Group	N/A	3.87	3.87
GRI GRI Bio	N/A	14.20	14.21
INTS Intensity Therapeutics	0.01	5.00	4.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ELOX Eloxx Pharmaceuticals	2.90%
FNCH Finch Therapeutics Group	21.77%
GRI GRI Bio	33.95%
INTS Intensity Therapeutics	3.74%

Insider Ownership

Company	Insider Ownership
ELOX Eloxx Pharmaceuticals	25.90%
FNCH Finch Therapeutics Group	44.90%
GRI GRI Bio	8.73%
INTS Intensity Therapeutics	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ELOX Eloxx Pharmaceuticals	N/A	690,000	510,000	N/A
FNCH Finch Therapeutics Group	190	1.61 million	885,000	No Data
GRI GRI Bio	1	1.77 million	1.62 million	Not Optionable
INTS Intensity Therapeutics	2,021	3.26 million	3.02 million	Not Optionable

GRI, FNCH, ELOX, and INTS Headlines

Recent News About These Companies

Intensity Therapeutics (INTS) Q2 2026 Earnings Call Transcript

August 12 at 6:45 PM | finance.yahoo.com

Intensity therapeutics targets INVINCIBLE-4 enrollment completion by end of 2027 while seeking $30M to finish INVINCIBLE-3

August 11, 2026 | seekingalpha.com

Intensity Therapeutics, Inc. (INTS) Q2 2026 Earnings Call Transcript

August 11, 2026 | seekingalpha.com

Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

August 11, 2026 | prnewswire.com

Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026

August 4, 2026 | prnewswire.com

Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)

July 15, 2026 | prnewswire.com

Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6

July 1, 2026 | prnewswire.com

Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's Why

May 27, 2026 | zacks.com

Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award

May 14, 2026 | prnewswire.com

Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 7, 2026 | prnewswire.com

Intensity Therapeutics Inc. (INTS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

May 1, 2026 | zacks.com

Intensity Therapeutics (INTS) price target decreased by 12.76% to 49.98

April 28, 2026 | msn.com

Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's What You Should Know

April 16, 2026 | zacks.com

Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation

April 15, 2026 | prnewswire.com

Intensity Therapeutics (INTS) price target decreased by 11.32% to 57.29

April 9, 2026 | msn.com

Intensity Therapeutics (INTS) price target decreased by 13.14% to 64.60

March 28, 2026 | msn.com

Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update

March 27, 2026 | prnewswire.com

Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US

March 24, 2026 | prnewswire.com

Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study

March 12, 2026 | prnewswire.com

Intensity Therapeutics Inc.: Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement

March 6, 2026 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GRI, FNCH, ELOX, and INTS Company Descriptions

Eloxx Pharmaceuticals NASDAQ:ELOX

$18.76 -0.31 (-1.63%)

As of 08/14/2026 04:00 PM Eastern

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company's lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.

Finch Therapeutics Group NASDAQ:FNCH

$7.30 0.00 (0.00%)

As of 08/14/2026

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

GRI Bio NASDAQ:GRI

$1.67 -0.10 (-5.65%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$1.70 +0.03 (+1.80%)

As of 08/14/2026 07:53 PM Eastern

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

Intensity Therapeutics NASDAQ:INTS

$3.96 -0.04 (-1.00%)

Closing price 08/14/2026 03:59 PM Eastern

Extended Trading

$4.05 +0.09 (+2.27%)

As of 08/14/2026 07:34 PM Eastern

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GRI, FNCH, ELOX, and INTS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GRI, FNCH, ELOX, and INTS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GRI, FNCH, ELOX, and INTS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GRI, FNCH, ELOX, and INTS Company Descriptions

Eloxx Pharmaceuticals NASDAQ:ELOX

Finch Therapeutics Group NASDAQ:FNCH

GRI Bio NASDAQ:GRI

Intensity Therapeutics NASDAQ:INTS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GRI, FNCH, ELOX, and INTS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GRI, FNCH, ELOX, and INTS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GRI, FNCH, ELOX, and INTS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GRI, FNCH, ELOX, and INTS Company Descriptions

Eloxx Pharmaceuticals NASDAQ:ELOX

Finch Therapeutics Group NASDAQ:FNCH

GRI Bio NASDAQ:GRI

Intensity Therapeutics NASDAQ:INTS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools